Boston Scientific Corporation has announced a €80 million investment in its Clonmel operations at an event celebrating the site’s 25th anniversary with Taoiseach Leo Varadkar on Friday.
The funding, supported by the Irish government through IDA Ireland, will go towards the continued expansion of the company’s medical technology manufacturing and research and development (R&D) capabilities.
The investment is expected to enable over 400 jobs in the coming years.
Boston Scientific employees based in Clonmel manufacture medical devices that support the treatment of more than 400,000 patients globally each year.
Products created in Clonmel help patients suffering from conditions such as heart disease, neurological disorders, kidney stones, and diseases of the pancreas, bile ducts and esophagus.
The company’s Clonmel site includes a Centre of Excellence for metal additives used in a range of electronic components for medical technology.
Hiring is underway for positions in highly specialised roles within production, engineering, quality, supply chain and R&D functions.
The new investment will increase office and manufacturing space and transition the entire site to source more than 90% of its energy needs from renewable sources.
This is part of the company’s broader sustainability commitment to achieve carbon neutrality by 2030.
“Boston Scientific has been steadily growing its footprint in Ireland for the past quarter century,” said Taoiseach Leo Varadkar.
“Ireland is a global leader in the life sciences sector, and the decision by the company to invest again in Clonmel shows real confidence in the talent and infrastructure available.”